<DOC>
	<DOCNO>NCT02023918</DOCNO>
	<brief_summary>Growth hormone well know cause change glucose regulation . People Laron syndrome bear without growth hormone receptor protect diabetes . Mice engineer without growth hormone receptor similarly protect diabetes . Conversely , people excessive amount growth hormone , patient acromegaly , increase risk type 2 diabetes . In acromegaly patient , treatment pegvisomant , medication reduces insulin like growth factor-1 blocking growth hormone receptor , significantly improve insulin resistance . Pegvisomant explore possibility treatment type 2 diabetes insulin resistance people without acromegaly . In study , investigator hope study metabolic effect pegvisomant people insulin resistance diabetes . Pegivosmant expect improve insulin resistance liver , fat muscle well decrease serum free fatty acid .</brief_summary>
	<brief_title>Role Growth Hormone Antagonism Modulating Insulin Sensitivity Subjects With Pre-diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>BMI 1835 Homeostatic model assessment insulin resistance ( HOMAIR ) &gt; 2.77 Able administer daily subcutaneous injection pegvisomant Pregnancy Breastfeeding last 6 month Liver function test great 3x upper limit normal unstable diet last 3 month unstable weight last 6 month unstable lipid lower regimen diabetes type 1 type 2 History major gastrointestinal surgery History pancreatic , liver , biliary , intestinal disease Fasting blood glucose &gt; 126 Fasting triglyceride &gt; 300 A1c &gt; 6.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Growth hormone antagonism</keyword>
</DOC>